

COVID-19 VACCINES

ISV VIRTUAL CONGRESS SERIES

3rd Congress Aug 25, 2020

Registration

www.ISVCongress.org

CONTACT

PHONE:

1-508-856-1179

EMAIL:

Info@ISVCongress.org

Program Aug 25, 9:00am – 12:00 noon (ET)

9:00 am Welcome and Introductions

Chair: Shan Lu, UMass Medical School/ISV

Linda Klavinskis, King's College London/ISV

Introduction of ISV Virtual Congress

Opening Session (20 min talks + 5 min Q&A)

Chair: Shan Lu, ISV

9:05am Myron Cohen, UNC-Chapel Hill

mAbs for COVID-19: Treatment and Prevention

9:30am Lynda Stuart, BMGF

Vaccine & mAbs Programs Supported by BMGF

Scientific Session One (18 min talks + 7 min Q&A)

Part I: Protein Vaccines

Chair: Xavier Saelens, University of Ghent/ISV

9:55am Keith Chappell, The University of Queensland

Molecular Clamp Stabilized Recombinant Protein

Subunit Vaccine for COVID-19

10:20am John Shiver, Sanofi-GSK

Recombinant and mRNA Vaccine Candidates

Against COVID-19

Part II: Novel Vaccine Technologies

Chair: Anna-Lise Williamson, University of Cape Town/ISV

10:45am Jacqueline Miller, Moderna

Moderna's Coronavirus Vaccine: Early Clinical Data and the COVE Phase III Efficacy and Safety Study

11:05am Brian Ward, Medicago

Development of Plant-Derived SARS-CoV-2 Virus-

Like Particle (CoVLP) Vaccine

Scientific Session Two (30 min panel discussion)

The Role of T and B Cell Responses and Vaccine Assay Standards for Determining Efficacy

Moderator: Margret Liu, ProTherImmune/ISV

11:30am Alessandro Sette, La Jolla Institute for Immunology

Michel Nussenzweig, The Rockefeller University

Neil Almond, NIBSC

Wrap up and Future ISV Virtual Congresses

12:00pm Linda Klavinskis, ISV

ISV Virtual Congress Series Co-Chairs

Linda Klavinskis, Margaret Liu, Shan Lu / ISV

Senior Advisors

Nick Jackson / CEPI, Susan Barnett / BMGF

